News about Industrial talks

Alvotech Reaches Global Settlement on Eylea Biosimilar

The settlement enables Alvotech and its partners to launch the biosimilar from January 1, 2026 in the UK and Canada, from May 1, 2026 in the EEA and other markets outside the US, and in Japan from May 2026 for select indications, expanding to all approved indications from November 1, 2026.

Industrial talks | 30/01/2026 | By News Bureau |  255

India's Pharma Industry Clocks INR 4.72 Lakh Crore Turnover in FY25: Economic Survey

India’s pharmaceutical industry delivered a strong performance in the financial year 2024–25, recording a total turnover of INR 4.72 lakh crore, according to the latest Economic Survey. The figures highlight the sector’s resilience and its growing role as a key contributor to India’s economy and global healthcare supply chain.

Industrial talks | 29/01/2026 | By Darshana |  1983

Bayer to Showcase Low-Dose MRI Contrast Innovation at ECR 2026

Bayer brings next-generation contrast agents and smart radiology solutions to ECR 2026, spotlighting progress in low-dose MRI imaging and clinical innovation.

Industrial talks | 28/01/2026 | By News Bureau |  434

EU Trade Pact Set to Boost Indian Pharma and Medical Device Exports

The recently finalised India–European Union Free Trade Agreement (FTA) is expected to significantly expand opportunities for India’s pharmaceutical and medical technology sectors by opening access to a USD 572 billion European healthcare market, Union Health Minister J.P. Nadda said.

Industrial talks | 28/01/2026 | By Darshana |  128

Pharma Leaders Outline Key Expectations Ahead of Union Budget 2026

Pharma industry leaders are urging the government to simplify GST on essential medicines, improve ease of doing business, enable easier access to long-term capital and provide greater policy clarity, amid more, in the upcoming Union Budget 2026.

Industrial talks | 28/01/2026 | By News Bureau |  418

Telangana Unveils Life Sciences Policy 2026-30

Telangana has unveiled its Life Sciences Policy 2026–30 with an ambition to rank among the world’s top five life sciences clusters by 2030, targeting USD 25 billion in investments while shifting the sector’s focus toward innovation-led growth and higher value creation.

Industrial talks | 22/01/2026 | By News Bureau |  412

Paracetamol Safe in Pregnancy, Confirms MHRA After Major Lancet Review Finds No Autism or ADHD Risk

The UK medicines regulator MHRA reaffirmed paracetamol as safe during pregnancy after a major Lancet review found no link to autism, ADHD or intellectual disability in children.

Industrial talks | 20/01/2026 | By News Bureau |  358

AstraZeneca Acquires Full Global Rights to AbelZeta's CAR-T Therapy C-CAR031 in USD 630 Million Deal

AstraZeneca has acquired AbelZeta Pharma’s China rights to CAR-T therapy C-CAR031 for up to USD 630 million, securing full global development and commercialisation rights for the liver cancer treatment.

Industrial talks | 20/01/2026 | By News Bureau |  160

Concept Life Sciences Appoints Dr Adam Davenport as CSO to Strengthen Leadership in Integrated Drug Discovery

Concept Life Sciences has appointed Dr Adam Davenport as Chief Scientific Officer (CSO), who brings over 25 years of expertise in life sciences and partnership management to advance the company’s leadership in integrated drug discovery.

Industrial talks | 20/01/2026 | By News Bureau |  235

Brazil and Nigeria Emerge as High-Growth Markets for Indian Pharma Exports

During the April–November period of the current financial year, pharmaceutical exports to Nigeria recorded a sharp increase, making it one of the fastest-growing destinations for Indian drug makers.

Industrial talks | 19/01/2026 | By Darshana |  250